SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Insightful Trends in Applied Materials Options Trading
- Analysis of Recent Options Activity for Adobe (ADBE)
- Investigation of MediaAlpha, Inc. (MAX) Unfolds Amid Concerns
- Investors Keep a Close Eye on Marqeta, Inc. (MQ) Developments
- QNB Corp. Announces Exciting Cash Dividend for Investors
- Ethereum’s Price Fluctuation and Market Insights Explained
- Barrick Gold's Commitment Amid Employee Arrests in Mali
- Market Overview: Stocks Mixed as Abercrombie & Fitch Struggles
- Market Trends and Options Activity in Deere Stocks
- Understanding the Current Options Activity for Exxon Mobil
- Insider Insights: ARM Holdings and Market Movements
- Mullen Automotive Innovates Electric Transportation Solutions
- WidePoint Corporation Achieves New Heights with Stock Surge
- Boston International Holdings Invites Stakeholders to 2024 AGM
- Maxpro Capital Stock Faces Tough Times, Drops to New Lows
- Insights into Recent Share Transactions at Picton Property
- Radware Ltd. Achieves 52-Week High Driven by Strong Growth
- WhatsApp's Legal Showdown with EU Privacy Regulators Explained
- Finland's Stock Market Experiences Notable Decline During Trade
- Insightful Options Analysis for Vistra: What Investors Should Know
- What Investors Should Know About Texas Instruments Options
- Understanding the Recent Movements in IES Hldgs' Options Market
- Tesla's Strategic Partnerships with Local Suppliers in China
- FMIC Welcomes Wayne Robinson as New CEO Amid Board Changes
- Exciting New Luxury Homes from Toll Brothers in Spring Hill, TN
- Wilks Development's Key Acquisition and Future Plans
- Current Status of Angola's Financial Plans and Bonds Market
- Dorian LPG Faces Market Challenges But Holds Strong Financials
- Union Bankshares Achieves New Heights with 52-Week High
- Finwise Bancorp Achieves 52-week High with Strong Growth Ahead
- Cintas Corporation Shares Reach Record High of $227.36
- Economic Implications of Proposed Tariffs on North America
- European Commission Reviews Fiscal Plans of France and Netherlands
- Copenhagen Market Rises as Key Sectors Achieve Gains
- Poland's WIG30 Index Experiences Minor Decline This Session
- CrowdStrike's Earnings Report: What Lies Ahead for Investors
- LeafLink's Strategic Acquisition of Leaf Trade to Boost Growth
- Exploring the Recent Decline of Bitcoin Cash and Market Trends
- Investor Interest Peaks in Marvell Tech Stock with Whales
- Insight into Occidental Petroleum's Market Activity and Trends
- Understanding Options Trading for United States Steel Shares
- Understanding Recent Trends in Eastman Chemical's Short Selling
- Understanding Short Interest for Hewlett Packard (HPE)
- Understanding Primerica's Short Interest Fluctuations
- Dell's Upcoming Earnings: Market Experts Look to Guidance
- Kohl’s Corporation Faces Declining Earnings Amid CEO Transition
- Maris Tech Reaches New Heights with Recent Market Surge
- Albion Crown VCT Secures Strong Shareholder Support at AGM
- Significant £2.25 Billion Treasury Gilt Auction Announced
- GTCR's Strategic Investment of $1.33 Billion in Tricentis